Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
- 2023
-
1. Planning and response to COVID-19: lessons from China and South-East Asia
- Prof. Annelies Wilder-Smith
- 2022
-
2. The emergence of the SARS-CoV-2 Omicron variant
- Prof. Emma Thomson
-
3. How is Omicron different?
- Prof. Emma Thomson
- 2021
-
5. Potential of ‘long-COVID’ in triggering chronic co-pathologies
- Dr. İmdat Eroğlu
-
6. SARS-CoV-2 monoclonal antibody testing in vivo
- Prof. Michael Diamond
-
7. mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals
- Prof. E. John Wherry
-
8. SARS-CoV-2 variants: implications for immunity and vaccine development
- Prof. Danny Altmann
-
10. SARS-COV-2 human monoclonal antibody therapy update
- Prof. James Crowe
-
11. Emergence of blood clotting disorders resulting from COVID vaccines inoculations
- Prof. Dr. Sabine Eichinger
-
12. SARS-CoV-2 evolution within and between individuals
- Prof. Katia Koelle
-
13. Identifying SARS-CoV-2 proteases
- Prof. Dr. Christa E. Müller
- Prof. Dr. Michael Gütschow
-
14. Genetic surveillance and the emergence of SARS-CoV-2 variants
- Prof. Emma Thomson
-
15. The COVID-19 outbreak: April 2021 update
- Prof. Jonathan Temte
-
16. ABO blood groups and SARS-CoV-2 susceptibility
- Dr. Sean Stowell
-
17. Impact of COVID-19 on neuropsychiatric disorders and mental health
- Prof. Anthony David
-
18. The immune system response to the SARS-CoV-2 virus: March 2021 update
- Prof. Paul Klenerman
-
23. SARS-CoV-2 vaccine rollout campaigns
- Prof. Luis Graca
-
25. Interspecies transmission of SARS-CoV-2
- Dr. Dalan Bailey
-
26. Complement activation in COVID-19
- Prof. Jeffrey Laurence
-
27. Human movement patterns and local spread of COVID-19
- Prof. Ben Cowling
-
28. SARS-CoV-2 mutations: phenotypes and implications for vaccine development
- Prof. David Montefiori
- 2020
-
29. The immune system response to the SARS-CoV-2 virus: December 2020 update
- Prof. Paul Klenerman
-
30. Triage and end of life care planning in COVID-19
- Prof. Robin Taylor
-
31. Natural killer cells as COVID-19 therapy
- Dr. Philippa Kennedy
-
32. Update on the SNG001 drug, an INFβ therapy for COVID-19
- Prof. Stephen Holgate
-
34. Identification of a new coronavirus-specific RNA export protein complex
- Dr. Montse Bárcena-Martin
-
35. The neurological symptoms of COVID-19
- Dr. Michael Zandi
-
36. Imperial College London’s saRNA Vaccine - COVAC1
- Dr. Katrina Pollock
-
37. Interferon-α2b as a therapy for COVID-19
- Prof. Eleanor N. Fish
-
38. Potential long-term health effects of a SARS-CoV-2 infection
- Prof. Danny Altmann
-
39. The COVID-19 coronavirus outbreak: October 2020 update
- Prof. Jonathan Temte
-
41. Rheumatic diseases and COVID-19
- Dr. Zachary Wallace
-
42. The cardiovascular complications of SARS-CoV-2 infection
- Prof. Srihari Naidu
-
43. Medical wearable devices for tracking symptoms of COVID-19
- Prof. John Rogers
-
44. Risk of re-emergence of COVID-19 after exit from lockdown
- Dr. Leonardo Lopez
-
45. The evolutionary origin of SARS-CoV-2
- Dr. Feng Gao
-
46. Predicting COVID-19 outbreaks by measuring SARS-CoV-2 RNA in sewage sludge
- Prof. Jordan Peccia
-
47. Approaches for elucidating genetic susceptibility to SARS-CoV-2
- Dr. Kenneth Baillie
-
48. The immune system response to the SARS-CoV-2 virus: July 2020 update
- Prof. Paul Klenerman
-
49. The impact of COVID-19 in the elderly and in care homes
- Dr. David Strain
-
50. Human challenge trials for vaccines against COVID-19
- Prof. Peter Smith
-
51. The development of SARS-CoV-2 vaccines
- Prof. Peter Hotez
-
52. Convalescent plasma therapy as a treatment for COVID-19
- Dr. Manu Shankar-Hari
-
53. Remdesivir COVID-19 clinical trial
- Prof. Mahesh Parmar
-
54. Nanotechnologies in the fight against coronaviruses
- Prof. Sabine Szunerits
-
55. The COVID-19 coronavirus outbreak: May 2020 update
- Prof. Jonathan Temte
-
56. INFβ therapy for COVID-19: the new SNG001 drug
- Prof. Stephen Holgate
-
57. Strategies for exiting the lockdown
- Prof. David McCoy
-
58. SARS-CoV-2 human monoclonal antibody therapy
- Prof. James Crowe
-
59. An FDA approved salivary test for SARS-CoV-2 infection
- Prof. Andrew Brooks
-
60. Development of an intranasal vaccine for SARS-CoV-2
- Dr. Scot Roberts
-
61. The immune system response to the SARS-CoV-2 virus: an update
- Prof. Paul Klenerman
-
62. A novel AIOD-CRISPR system for diagnosis of SARS-CoV-2
- Prof. Changchun Liu
-
63. Development of PRO-140 (Leronlimab) as a treatment for COVID-19
- Dr. Jacob Lalezari
-
64. COVID-19 epidemiology and potential treatments: follow up interview
- Prof. Ralph Baric
-
65. SARS-CoV-2 vaccine development: where are we now?
- Prof. Gary Kobinger
-
66. SARS-CoV-2: What we need to know and possible future therapies
- Prof. Stanley Perlman
-
67. SARS-CoV-2 vaccine: current biological targets and considerations
- Dr. Adolfo Garcia-Sastre
-
68. The current understanding of the biology of the SARS-CoV-2 virus
- Prof. Peter Palese
-
70. The immune system response to the SARS-CoV-2 virus
- Prof. Paul Klenerman
-
71. SARS-CoV-2 vaccine development
- Prof. Stanley Plotkin
-
72. The COVID-19 outbreak: an update on the SARS-CoV-2 virus
- Prof. Ralph Baric
-
73. The COVID-19 coronavirus outbreak: a current view
- Prof. Jonathan Temte
-
74. The COVID-19 coronavirus outbreak: March 2020 update
- Prof. Jonathan Temte
Topics Covered
- The pathogenesis of COVID-19 mediated by complement activation
- Indicators for complement activation in COVID-19
- The interaction between coagulation and complement cascades
- When to treat patients with anti-complement drugs
Biography
Dr. Jeffrey Laurence is a Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medical College, Attending Physician at New York Presbyterian Hospital, and Director of the Laboratory for AIDS Virus Research at those institutions. He is the Senior Scientist for Programs at amfAR, The Foundation for AIDS Research (co-founded by Dr. Mathilde Krim and Dame Elizabeth Taylor). He is also Editor-in-Chief of Translational Research (the Journal of Lab and Clinical Medicine) and for AIDS Patient Care and STDs. His current research focuses on mechanisms of HIV and HIV-treatment-associated cardiovascular and renal disease, the thrombotic microangiopathies associated with complement activation, and microvascular endothelial cell injury in HIV and other disorders including, most recently, COVID-19.
Dr. Laurence received his B.A. summa cum laude from Columbia University in 1972, and his M.D. with honors from the University of Chicago Pritzker School of Medicine in 1976. He was elected a Rhodes Scholar to Oxford University in 1973 and was a Henry Luce Scholar at the Institute for Cancer Research in Osaka, Japan, from 1974-1975. He completed a residency in internal medicine, followed by fellowships in hematology and oncology at The New York Hospital and a research fellowship in immunology at The Rockefeller University, where he first became involved in AIDS.
Dr. Laurence is a recipient of the Clinician-Scientist Award of the American Heart Association, the William S. Paley Fellowship in Academic Medicine, and an “Award of Vision” from the Red Ribbon AIDS Foundation. He is a member of the American Society for Clinical Investigation.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Laurence, J. (2021, January 20). Complement activation in COVID-19 [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 9, 2025, from https://doi.org/10.69645/JPGE9884.Export Citation (RIS)
Publication History
- Published on January 20, 2021
Financial Disclosures
- Prof. Jeffrey Laurence has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Microbiology
Transcript
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)